Sector
Expertise
We simplify the process of collaborating with specialists, including regulatory pathway expertise, as well as finding resources, programs and assistance available to help new and early-stage businesses.
Coordinated by
GU Ventures
Exploring the How-To of
Commercializing
Commercializing
New Modalities
Can leading organizations collaborate to ensure access to quality resources, engage with complementary organizations, and facilitate access to capital? We believe so!
A Unique Constellation of Life Science Organizations
New Modality Support (NMS) is a collaborative project supporting individual research within the national drug development initiatives OligoNova and CCRM Nordic. It focuses on therapeutic oligonucleotides and advanced therapies (ATMP). The constellation members combine their unique strengths to support early-stage life science companies in the Nordic region.
Utilizing research is crucial. Our researchers’ ideas and solutions can contribute to a better future—if given the opportunity to realize them. NMS plays an important role in achieving this
Sharing Knowledge to
Provide Better Support
Success in therapeutic oligonucleotide and ATMP-specific drug development requires new knowledge and understanding. Incorporating research and commercialization strategies early increases a project's chance of success.
Learn more
Sector
Funding and
Investments
Attractive and clear packaging of the investment case is important in order to attract relevant investors. We help early-stage businesses navigate the investor landscape and build strong investor-company relationships.
Fostering
Collaboration
NMS helps early-stage businesses in getting access to complementary organizations within the life science ecosystem such as incubators, arenas, hospitals and universities.
Want to Learn
More?
Learn more about the focus areas of NMS and what we do to support early-stage researchers and innovators.
Read more